A39413th Euro Abstracts 93.7% in age group 1 (0 ≤ 12 years) to 83.3% in age group 5 (older than 65 years). In general the lowest average refi ll-based adherence rates were obtained with medicine items containing phenobarbitone and vitamin B1 (52.0% ± 37.8); phenobarbitone (63.5% ± 47.2); primidone metabolites (69.7% ± 47.2%); clonazepam (77.8% ± 184.8) and carbamazepine (80.9% ± 151.1) CONCLUSIONS: Most of the anti-epileptic drugs had unacceptable low refi ll-adherence rates. Refi ll-adherence rates of anti-epileptic drugs decreased with an increase in the age of patients.
PND33 REFILL-ADHERENCE RATES OF ANTIPARKINSON MEDICATION IN THE PRIVATE HEALTH CARE SECTOR OF SOUTH AFRICAVan der Merwe S, Lubbe MS, Du Plessis JM, Bekker E North-West University, Potchefstroom, South Africa OBJECTIVES: To investigate the prevalence of unacceptable refi ll-based adherence rates with antiparkinson medicine items. METHODS: A retrospective drug utilization study was performed on medicine claims data of a pharmacy benefi t management company in South Africa during January 1, 2005 until December 31, 2008. Refi llbased adherence rates were calculated for 8 768 antiparkinson medicine items that were prescribed more than once during a four-year period (January 1, 2005 to December 2008). The refi ll-based adherence rate was calculated per trade name by using the following equation: Refi ll-Adherence rate = (total number of days of antiparkinson medicine items supplied-days supplied at the last refi ll)/(date last claimed-date fi rst claimed). (RSA Rand(R)/$US = 6.8595 on 31 Dec. 2007). [RSA Rand (R)/$US = 6.38112 (2005); 6.78812 (2006); 7.06926 (2007) and 8.27505 (2008)] RESULTS: A majority of antiparkinson medicine items (53.50%, n = 4,691) had unacceptably low refi ll-adherence rates below 90%, that accounted for 41.62% (n = R16,398,512.00) of the total cost (N = R39,402,898.20) of all antiparkinson medicine items included in this study. Only 36.78% (n = 3225) of antiparkinson medicine items had acceptable refi ll-adherence rates between 90% and 110%. Those with unacceptable high refi lladherence rates accounted for 9.72% (n = 852) of all antiparkinson medicine items and represented 6.5% (n = R2,574,597) of the total cost. No practical signifi cant difference in the average refi ll-adherence rates was found between male (93.99% ± 186.99) and female (90.83% ± 175.21) patients. Biperidien, carbidopa/levodopa, and levodopa/benserazide containing products had on average unacceptable low refi lladherence rates (<90%). CONCLUSIONS: Although poor obedience to treatment schedules adds up to aggravation of Parkinson's disease leading to death and amplifi ed health care cost, it seems that the refi ll-adherence rate of antiparkinson medicine items is not very favourable
PND34 A PSYCHOMETRIC EVALUATION OF THE REVISED SCOPA DIARY CARD IN PARKINSON'S DISEASE PATIENTSBuck PO 1 , Castelli-Haley J 1 , White RE 1 , Rendas-Baum R 2 , White MK 2 1 Teva Neuroscience, Kansas City, MO, USA; 2 QualityMetric Incorporated, Lincoln, RI, USA OBJECTIVES: The Sc...